报价延迟最少15分钟:2025/07/18 16:33 EDT
盘后时段
|
||||
|
8.73 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.73
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.04/-21.75
|
|
企业价值
5.19M
|
| 资产负债 |
|
每股账面净值
-5.34
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/18 16:33 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables itto integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. |
